Royalty Report: Drugs, Cancer, Biotechnology – Collection: 29511

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology
  • Diagnostic
  • Diagnostic Substances

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29511

License Grant
University hereby grants LICENSEE an exclusive right and license to utilize the LICENSED TECHNOLOGY (i) to develop LICENSED PRODUCTS, LICENSED PROCESSES, and IMPROVEMENTS, (ii) to manufacture, sell, lease and otherwise transfer in vitro serum diagnostic LICENSED PRODUCTS and other LICENSED PRODUCTS, LICENSED PROCESSES, and IMPROVEMENTS, and (iii) to practice LICENSED PROCESSES within the TERRITORY as authorized in this Agreement until such time as this Agreement expires or is terminated.
License Property
University is the sole owner of certain intellectual property rights known as 'Thymidine Kinase Isoenzyme Diagnostics'.

Thymidine Kinase-1, or TK1, test may enable early detection and monitoring of several types of common cancers in an efficient and cost effective manner.

The BIOLOGICAL MATERIAL known as 'Thymidine Kinase Hybridomas' consists of the following hybridoma cell line clones which produce anti-thymidine kinase monoclonal antibodies.

IPSCIO Record ID: 5202

License Grant
The University granted the Licensee an exclusive right and license to utilize the Licensed Technology to develop the Licensed Products.
License Property
The patented technology refers Thymidine Kinase Isoenzyme Diagnostics and Thymidine Kinase Hybridomas. Thymidine Kinase – 1 or TK1 is a cancer screening technology.  A kit using the ELISA format, would require only a small blood sample and could also be incorporated into a standard blood test panel. The ELISA format is a fundamental tool of clinical immunology, based on the principle of antibody-antibody interaction.   A kit using this format provides easy visualization of results, detecting the presence and amount of TK1, and can be completed without the expense and other problems of using radioactive materials.

Thymidine kinase is an enzyme, a phosphotransferase (a kinase): 2'-deoxythymidine kinase, ATP-thymidine 5'-phosphotransferase, EC 2.7.1.21.[2][3] It can be found in most living cells. It is present in two forms in mammalian cells, TK1 and TK2. Certain viruses also have genetic information for expression of viral thymidine kinases.

Field of Use
The Licensee shall develop a serum Enzyme-Linked Immunosorbent Assay (ELISA) diagnostic kit for the detection of Thymidine Kinase-1 Isoenzyme.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.